CR Bard (NYSE: BCR) reported earnings on April 23. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended March 31 (Q1), CR Bard beat slightly on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue grew slightly. Non-GAAP earnings per share contracted. GAAP earnings per share contracted significantly.

Margins dropped across the board.

Revenue details
 CR Bard reported revenue of $740.3 million. The 17 analysts polled by S&P Capital IQ anticipated a top line of $729.5 million on the same basis. GAAP reported sales were the same as the prior-year quarter's.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $1.44. The 19 earnings estimates compiled by S&P Capital IQ anticipated $1.42 per share. Non-GAAP EPS of $1.44 for Q1 were 11% lower than the prior-year quarter's $1.61 per share. GAAP EPS of $1.08 for Q1 were 33% lower than the prior-year quarter's $1.60 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 60.1%, 160 basis points worse than the prior-year quarter. Operating margin was 22.9%, 450 basis points worse than the prior-year quarter. Net margin was 12.3%, 670 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $749.6 million. On the bottom line, the average EPS estimate is $1.46.

Next year's average estimate for revenue is $3.06 billion. The average EPS estimate is $6.29.

Investor sentiment
 The stock has a five-star rating (out of five) at Motley Fool CAPS, with 270 members out of 279 rating the stock outperform, and nine members rating it underperform. Among 102 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 101 give CR Bard a green thumbs-up, and one give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on CR Bard is hold, with an average price target of $104.75.

Is CR Bard the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.